The White House announced a drug pricing deal on April 23 with Regeneron, the final holdout among large pharmaceutical companies to sign most favored nation pricing deals with the Trump administration.
Regeneron became the 17th large pharmaceutical company to sign a drug pricing agreement after receiving letters from President Donald Trump in July.
During an Oval Office announcement Thursday with Health and Human Services officials and Regeneron executives, Trump touted the deal as the latest example of his administration's efforts to lower drug prices for Americans.
Trump said the 17 drug companies that have agreed to most favored nation pricing deals represent 80% of brand-name drugs marketed in the U.S.
"This will result in the largest drop in prescription drug prices in the history of the United States of America," Trump said.
